Dior Plus

Quick links to important sections

Dior Plus

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dior Plus

Property Description
Active ingredient Glibenclamide, Metformin Hydrochloride
Form Oral Tablet
Pharmacological class Antidiabetic Agent (Sulfonylurea/Biguanide)
Common use Managing high blood glucose in Type 2 Diabetes Mellitus
Origin Synthetic

Dior Plus is a synthetic, prescription-only medication categorized as an oral antihyperglycemic agent. This medicine is supplied as an oral tablet and is taken by mouth to help adults manage high blood glucose levels associated with Type 2 Diabetes Mellitus. It is defined as a fixed-dose combination product, which merges two distinct types of active substances into one single dosage form. The effectiveness of this dual-agent approach is clinically recognized for providing comprehensive glucose control compared to single-agent therapies.


What Is the Composition and Pharmacological Class of Dior Plus?

The medicine's composition includes two core active ingredients: Glibenclamide (a sulfonylurea) and Metformin Hydrochloride (a biguanide). The inclusion of Metformin Hydrochloride is a cornerstone of therapy, as it is a highly effective agent for reducing the liver's glucose production and enhancing insulin sensitivity. Common brands that share this two-drug formulation include Glucovance and Glibomet, highlighting the established utility of the Glibenclamide/Metformin fixed-dose combination.


General Purpose of This Combination Medicine

The general purpose of Dior Plus is to help patients effectively manage and sustain appropriate blood glucose levels. This fixed-dose combination is typically selected for patients who require the synergistic effect of both insulin stimulation and improved glucose utilization. One component primarily helps increase the body's natural insulin release, while the other reduces the production of sugar by the liver and enhances cellular sensitivity to insulin. This dual mechanism ensures that the medication directly supports the body's ability to process and utilize sugar, which is a foundational requirement for managing Type 2 Diabetes Mellitus successfully.

What side effects are possible with Dior Plus?

Possible Side Effects and Safety Information

Official Adverse Reaction Scope

The safety profile of the Glibenclamide/Metformin combination is defined by adverse reactions classified in official government regulatory documents. The most frequent events are categorized by the body system affected, primarily Metabolism and Nutrition Disorders and Gastrointestinal Disorders.

  • Very Common (ge 1/10) effects include Hypoglycaemia (low blood glucose), a key risk of the Glibenclamide component, and Diarrhoea.
  • Common (ge 1/100 to < 1/10) effects often involve the gastrointestinal system, such as nausea, vomiting, abdominal pain, and decreased appetite, which are typically more common at the start of treatment.

Serious Adverse Reactions and Safety Constraints

The regulatory label documents two principal serious risks that require defined safety constraints:

  1. Lactic Acidosis: A rare but potentially life-threatening metabolic complication associated with the Metformin component. This risk is highlighted by specific warnings, particularly for patients with compromised kidney function.
  2. Severe Hypoglycaemia: Represents a medical emergency, linked to the sulfonylurea component.

The use is contraindicated in patients with severe renal impairment (reduced kidney function) due to the increased risk of Lactic Acidosis. Additionally, the label requires temporary discontinuation prior to specific medical procedures, such as intravascular iodinated contrast imaging, and cautions against excessive alcohol intake.

Population- and Exposure-Related Notes

The safety profile includes specific notes for certain patient groups and duration of use. Older adults, for instance, may require frequent assessment of renal function. Long-term exposure is associated with the potential for reduced Vitamin B12 levels and anaemia.

Overdose and Emergency Response

The official regulatory documentation defines the Dior Plus overdose profile based on the distinct toxic effects of its two active components, Glibenclamide and Metformin. An overdose is associated with two primary, potentially life-threatening outcomes: severe hypoglycemia and lactic acidosis.

Overdose of the Glibenclamide component, a sulfonylurea, typically manifests as profound and prolonged hypoglycemia (low blood sugar), which can lead to serious central nervous system symptoms, including confusion, somnolence, seizures, and ultimately, coma. The Metformin component primarily poses a risk of lactic acidosis, a severe metabolic complication. Initial symptoms of lactic acidosis are often non-specific and may include generalized malaise, muscle pain, abdominal distress, nausea, and vomiting.

Immediate medical attention is required upon the suspicion of overdose. Regulatory guidance mandates contacting emergency services if symptoms of severe hypoglycemia or lactic acidosis are present, or if an individual becomes unresponsive. Supportive management involves addressing these specific toxicities. For severe hypoglycemia, the official procedure is intravenous glucose administration. Due to the risk of delayed hypoglycemia recurrence, regulatory bodies require extended hospital monitoring. For severe Metformin-related toxicity, including profound lactic acidosis, hemodialysis is the described procedure to correct the acidosis and remove accumulated Metformin from the circulation. Overdose risk is particularly elevated in patients with existing renal impairment due to decreased clearance of Metformin.

Therapeutic Uses of Dior Plus

The Dior Plus combination is commonly used to help with the management of Type 2 Diabetes Mellitus in adults. It is applied in contexts where the condition is characterized by a systemic imbalance and cannot be controlled by diet and exercise alone. The primary function is addressing hyperglycemia, the core condition marked by persistently high sugar levels in the bloodstream. The dual-agent approach contributes to easing the overall symptom load by providing support that helps stabilize blood glucose.

The medicine is considered relevant for easing the symptoms related to systemic imbalance in adult patients who show inadequate glycemic control after initial treatment with a single oral agent. The common clinical situations where it is relevant include high blood glucose, elevated HbA1c levels, and the need for sustained metabolic stability. The treatment supports efforts toward stable long-term glycemic targets. This stable state assists with maintaining functional stability and may assist with reducing the patient's future risk of complications, including symptoms linked to organ-specific functional stress.

“This therapy is generally used when additional support is needed to achieve the required level of metabolic control.”

Quick Fact: Relief for Hyperglycemia (High Blood Sugar)

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Dior Plus

Populations for whom use is allowed: This fixed-dose combination medicine is indicated for use by adults (18 years and older) diagnosed with Type 2 Diabetes Mellitus. It is approved for patients whose blood glucose control remains inadequate despite treatment with diet, exercise, or a single oral antidiabetic agent.

Absolute Contraindications: The medicine must not be used in patients with:

  • Severe Renal Impairment (eGFR below 30 mL/min/1.73 m^2).
  • Type 1 Diabetes Mellitus or any form of Metabolic Acidosis (including diabetic ketoacidosis).
  • Conditions causing tissue hypoxia (e.g., acute heart failure, shock) or severe Hepatic Impairment.
  • Hypersensitivity to Glibenclamide, Metformin, or other sulfonylureas.

Age- and Condition-Based Restrictions:

  • Pediatric Use: Safety and efficacy have not been established in patients younger than 18 years.
  • Older Adults: Conservative dosing is recommended, and renal function must be assessed more frequently. Initiation in patients aged 80 years and older is restricted unless renal function is confirmed as adequate.
  • Pregnancy and Lactation: Use is not recommended during either pregnancy or breastfeeding, as officially documented in regulatory labeling.
  • Medical Procedures: The medicine must be temporarily discontinued before surgical procedures or radiologic studies involving intravascular iodinated contrast materials.

What should I know about interactions with other medicines?

Dior Plus (Glibenclamide/Metformin) presents a clear profile of officially documented interaction patterns based on regulatory classification. The highest severity restrictions involve formally contraindicated combinations such as Miconazole (systemic or oromucosal gel), which significantly increases the hypoglycemic effect of Glibenclamide with a risk of coma. Co-administration with Bosentan is also prohibited due to documented risks of reduced efficacy for both agents. The pharmacokinetic exposure of the Metformin component is increased by inhibitors of OCT2 and MATE renal transporters. Medicines like Cimetidine, Ranolazine, Vandetanib, and Dolutegravir compete for these systems, elevating Metformin plasma accumulation. Conversely, Acidic drugs like Phenylbutazone and Warfarin may displace Glibenclamide from protein binding sites, potentially enhancing its action.

Mandatory timing rules apply to procedures using iodinated contrast media, requiring discontinuation of Metformin at or prior to the imaging procedure and withholding it for 48 hours afterward to mitigate lactic acidosis risk. Dosing must also be separated from Colesevelam by at least 4 hours to maintain Glibenclamide absorption. Finally, excessive alcohol intake is restricted due to its ability to potentiate Metformin's effect on lactate metabolism and increase the Glibenclamide component's hypoglycemic reaction. Interaction severity related to accumulation risk is increased in geriatric patients due to age-related changes in renal clearance.

Mechanism of Action

How Dior Plus Works: Mechanism of Action

The medicine exerts its physiological effect through two distinct and complementary mechanisms, involving two pathways that modulate insulin secretion and peripheral insulin responsiveness.


Pancreatic beta-Cell Secretagogue Action

The Glibenclamide component initiates a direct secretagogue action by binding to and blocking the ATP-sensitive potassium (K ATP ) channel on pancreatic beta-cells. This molecular event forces membrane depolarization, triggering the release of pre-formed insulin. This mechanism ensures an immediate increase in the supply of the hormone required for glucose homeostasis, but its action is constrained by the remaining beta-cell functionality.


Hepatic and Peripheral AMPK Modulation

The Metformin component operates as a sensitizer, targeting core metabolic pathways primarily within the liver and muscle tissue. Its action begins with the inhibition of the mitochondrial Complex I, which activates the cellular energy sensor, AMP-activated protein kinase (AMPK). This activation suppresses the liver's gluconeogenesis (glucose production) while simultaneously increasing the capacity of peripheral cells to use circulating insulin by enhancing glucose transporter activity ( GLUT4 translocation).


Synergistic Dual-System Effect

This combination leverages a multi-pathway synergy where Glibenclamide boosts hormone availability, and Metformin enhances tissue utilization while suppressing endogenous glucose production. This coordinated, dual-system modulation results in a balanced control of pathways that influence glucose processing.

Dosage and Administration Information

How to Use Dior Plus

This section outlines the general principles for administering Dior Plus, a fixed-dose combination of Glibenclamide and Metformin.


Administration and Dosage Regimen

The approved route of administration for this medicine is oral via an immediate-release tablet. The dosage schedule requires administration in divided doses daily, which must be taken with meals (such as breakfast, lunch, and/or dinner) to optimize its use and minimize gastrointestinal effects.

Initial dosing for patients beginning therapy typically starts at 1.25 mg Glibenclamide / 250 mg Metformin once or twice daily. For patients switching from single-agent treatments, a starting dose of 2.5 mg/500 mg or 5 mg/500 mg twice daily is common. Dose adjustments, or titration, are conducted conservatively, usually no more frequently than every two weeks, to ensure stable glucose control and patient tolerance. The established maximum daily dose is 20 mg Glibenclamide / 2000 mg Metformin.


Special Procedural Constraints

The usage instructions include specific rules for clinical procedures. The Metformin component must be discontinued before or at the time of procedures that involve the injection of iodinated contrast media or certain types of surgery (general, spinal, or epidural anaesthesia). Therapy may only be restarted 48 hours afterward once renal function has been re-evaluated and confirmed to be stable.

Furthermore, the dose for older adults must be initiated conservatively, and their renal function must be assessed frequently throughout the course of treatment. The need for administration with a meal that contains sufficient carbohydrate content is also noted to support proper use of the Glibenclamide component.

Recent Clinical Evidence

Dior Plus: Recent Clinical Evidence


Research Focus and Study Parameters

Dior Plus is a fixed-dose combination of Metformin and Glibenclamide, which are commonly prescribed for the management of Type 2 Diabetes Mellitus. Research on this combination primarily examines its effect on measurable outcomes in participants who have not achieved adequate glycemic control through diet and exercise alone.

Overall, studies have documented changes in short-term and long-term glycemic indicators, including HbA1c (glycated hemoglobin) levels and Fasting Plasma Glucose (FPG).

Key Findings from Clinical Trials

Glycemic Control

Multiple clinical trials have evaluated the dual action of the combination therapy. Metformin is documented to reduce glucose production in the liver and enhance the body's response to insulin. Glibenclamide, a sulfonylurea, works by stimulating the pancreas to release more insulin.

Studies involving adult patients with Type 2 Diabetes documented statistically significant findings on measures of HbA1c reduction when compared to either monotherapy (Metformin or Glibenclamide alone) or placebo. The co-administration is associated with achieving lower blood glucose targets.

Risk of Complications

Research has investigated whether improved long-term glycemic control achieved with this class of medication may be associated with changes in the risk of certain macrovascular and microvascular complications, such as kidney damage, vision problems, and nerve issues, that are related to uncontrolled diabetes.

Safety Profile and Adverse Events

Studies documented adverse events related to both components. Common adverse events include gastrointestinal issues such as diarrhea, nausea, and stomach pain, which are frequently reported with Metformin. Because of the Glibenclamide component, hypoglycemia (low blood sugar) is a potential documented risk, particularly when used with other anti-diabetic medications or if meals are delayed.

Clinical trials generally focused on participants without severe kidney or liver impairment, as the compound's suitability for individuals with these conditions remains under investigation in this body of research.

Key Studies & References

  1. NICE Guideline NG28: Type 2 diabetes in adults: management
  2. World Health Organization (WHO) Model Lists of Essential Medicines (Relevant Sections on Diabetes Management)

Frequently Asked Questions (FAQ)

Common questions about Dior Plus (FAQ)

Q: What is the main difference between Dior Plus and the regular Dior medicine?

A: Dior Plus is defined in official documents as a fixed-dose combination containing two active ingredients, Glibenclamide and Metformin. This differs from a monotherapy medicine, which contains only one active substance. The combination provides two complementary mechanisms to help manage blood glucose levels.


Q: How long do side effects from Dior Plus usually last after starting treatment?

A: Common side effects, such as gastrointestinal issues like diarrhea or nausea, are often reported most frequently at the start of treatment. According to official information, these effects are generally documented to resolve over time.


Q: What is the role of the 'Plus' ingredient in Dior Plus?

A: The term 'Plus' signifies that the medicine is a fixed-dose combination containing both Glibenclamide and Metformin. These two components work together: Glibenclamide primarily stimulates insulin release, while Metformin is an agent that enhances insulin sensitivity.


Q: Is Dior Plus safe to use for women who are pregnant or breastfeeding?

A: Official regulatory labeling states that the use of this medicine is not recommended during pregnancy or breastfeeding. This recommendation is based on the fact that safety and efficacy data have not been fully established in these specific populations.


Q: Is Dior Plus available as a generic medicine?

A: Yes, the formulation containing Glibenclamide and Metformin Hydrochloride is a long-established therapy. This combination is widely available as a generic medicine under various trade names.


Q: Can I crush or split the Dior Plus tablet if I have trouble swallowing?

A: The tablets are typically intended to be swallowed whole with water. Regulatory instructions usually advise against crushing, chewing, or splitting the tablet, as directed in the official prescribing information.


Q: Can Dior Plus be taken with common over-the-counter pain relievers?

A: Official documents mention that certain Acidic drugs may potentially affect the action of the Glibenclamide component by competing for binding sites. Official information emphasizes the importance of informing a healthcare provider about all medicines being taken, including over-the-counter pain relievers.


Q: What should be done if I suspect an interaction between Dior Plus and another drug?

A: Official guidance emphasizes the importance of consulting with a healthcare professional immediately if a drug interaction is suspected or if new or worsening symptoms are experienced. This is necessary for a proper assessment.


Q: Do people typically gain or lose weight when taking Dior Plus?

A: Clinical trial data on changes in body weight with this combination are often reported as not statistically significant compared to a placebo. However, the Metformin component, in studies, is sometimes documented to be associated with a modest weight loss.


Q: What is the importance of taking Dior Plus at the same time each day?

A: Taking the medicine at the same time each day is recommended to help maintain consistent levels of the medication in the bloodstream. This consistency supports stable blood glucose control, which is the primary goal of the therapy.


Q: How long does the effect of Dior Plus typically last?

A: The active ingredients in the medicine have plasma elimination half-lives in the range of 4 to 9 hours. This property informs the typical requirement for a twice-daily dosing regimen to maintain consistent glucose management.


Q: Is Dior Plus a medicine that needs to be taken every day?

A: Since the medicine is indicated for the chronic management of Type 2 Diabetes Mellitus, it is typically used for long-term treatment. It is taken every day as part of an ongoing treatment plan.


Q: What should I do if I forget to take a dose of Dior Plus?

A: If a dose is missed, patients are generally instructed not to take a double dose to make up for the missed one. The patient is typically directed to resume their usual schedule with the next planned dose.


Q: Can Dior Plus cause headaches or dizziness?

A: Official adverse event profiles sometimes list headache as a documented side effect. Dizziness is not listed as a common effect but is a known symptom associated with the primary documented risk of hypoglycemia (low blood sugar).


Q: Does Dior Plus have a risk of dependence or withdrawal if stopped suddenly?

A: The medicine is not associated with dependence or abuse risk. However, stopping it suddenly without alternative treatment may lead to a loss of blood sugar control and the potential for associated complications.


Q: Does the color or shape of the Dior Plus pill have any significance?

A: Yes, official regulatory information indicates that the tablets are often film coated and use different colors or markings on the pill. This differentiation is designed to help distinguish between the various available dosage strengths of the medicine.


Q: Is Dior Plus meant for short-term or long-term use?

A: The medicine is indicated for the management of Type 2 Diabetes Mellitus, which is a chronic, long-term condition. It is therefore typically used for long-term management under a healthcare provider's direction.


Q: What is considered an overdose of Dior Plus?

A: The most concerning symptoms associated with an overdose relate to the severe risks of hypoglycemia and lactic acidosis. Documented symptoms can include extreme tiredness, vomiting, abdominal pain, deep rapid breathing, and an abnormally fast or slow heartbeat.


Q: What should I do if a side effect of Dior Plus does not go away?

A: Official patient safety guidance indicates the importance of consulting with a healthcare professional if any side effect persists, worsens, or causes concern. A provider can then assess the situation and determine the appropriate action.


Q: Are there different strengths available for Dior Plus?

A: Yes, this fixed-dose combination is manufactured and available in multiple dosage strengths. These strengths combine different milligram amounts of the Glibenclamide and Metformin components to allow for appropriate treatment titration.


Q: What is the chemical name of the active ingredient in Dior Plus?

A: The medicine contains two core active substances. They are known by the chemical/generic names Glibenclamide (also known as Glyburide) and Metformin Hydrochloride.


Q: What are the storage guidelines for Dior Plus medicine?

A: Official regulatory documents specify that the medicine must be stored at a controlled room temperature (typically below 30 C). It should be kept in its original container, protected from light and moisture, and safely out of the sight and reach of children.


Q: What is the typical timeframe for people to notice the effects of Dior Plus?

A: The full clinical benefit of the medicine is measured by changes in long-term blood glucose indicators, such as HbA1c. These results are typically assessed after several weeks to months of therapy, following a gradual dose adjustment process.


Q: Where can I find reliable, official information about the research on Dior Plus?

A: Reliable, official information about the research and clinical trials can be found on regulatory body websites like the FDA and the European Medicines Agency (EMA). Information is also available through public research registries such as ClinicalTrials.gov.


Q: Is Dior Plus approved in countries outside of the US?

A: Yes, the fixed-dose combination of Glibenclamide/Metformin is approved and regulated for use in the treatment of Type 2 Diabetes Mellitus in multiple countries by various international regulatory bodies, including the EMA and MHRA.


Q: Is it safe to consume alcohol in small amounts while on Dior Plus?

A: Official warnings specifically restrict the use of excessive alcohol intake because it can potentially increase the severe risk of lactic acidosis. Official information suggests consulting a healthcare provider to determine what amount of alcohol, if any, may be appropriate for an individual's specific health status.

How should Dior Plus be stored and disposed of?

How to Store and Dispose of Dior Plus?

This medicine must be stored strictly according to its official labeled requirements to ensure its stability and effectiveness.

Storage Domain Official Requirement
Temperature & Protection Store at a cool room temperature, typically below 30 C or as specified on the package. The product must be protected from light and moisture by remaining in its original container.
Handling & Access Keep the container tightly closed and keep the medicine out of the sight and reach of children and pets. Check the expiration date and do not use expired or damaged medicine.
Disposal Disposal of Dior Plus must be done in accordance with local requirements. Unused or expired medication must not be flushed down the toilet or thrown into household waste, to protect the environment.

These mandated conditions—covering temperature, protection from environmental factors, and final safe disposal—are essential for maintaining the integrity of the medicinal product throughout its shelf life, as defined by regulatory documentation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dior Plus found in:

A-Z Index: